Navigation Links
Key molecule suppresses growth of cancerous liver tumors, Mayo study finds
Date:2/13/2013

ROCHESTER, Minn. -- A molecule already implicated in a number of diverse cellular functions can suppress the growth of tumors in the liver, a Mayo Clinic Cancer Center study has found. Its name is IQGAP1, and when the molecule is active in the cells that surround a tumor cell, this "tumor microenvironment" becomes less hospitable to cancer growth. When the molecule is deficient, cancer thrives.

Results of the study appear in the Journal of Clinical Investigation. The findings give new insight into cancer metastasis, the ability of a tumor to spread from its primary site to distant organs such as the brain, lung or liver. The results also point to new targets for preventing or treating liver metastases, the major cause of death from cancer.

"Tumor cells are intelligent -- they talk to the cells in their surroundings to change the way they behave and make the environment supportive of cancer growth. If we can disrupt the communication between the tumor cells and the tumor microenvironment, we can prevent tumor growth or metastasis in the liver," says senior study author Ningling Kang, Ph.D., a biochemist and molecular biologist at Mayo Clinic.

For certain solid tumors, about 70 to 90 percent of the tumor mass is made up of microenvironment -- a complex mix of noncancerous cells, secreted extracellular matrix proteins, and tumor-promoting signaling molecules. This tumor microenvironment supports tumor growth and drug resistance. Mechanisms regulating the tumor microenvironment are not well understood.

IQGAP1 controls the shape and movement of cells. To study the effects of this molecule on liver metastases, Dr. Kang and her colleagues implanted tumor cells into the livers of mice genetically engineered to lack the molecule.

The implanted tumor cells still had the molecule, but the cells that made up the tumor microenvironment did not. When researchers compared the progression of cancer between mutant and normal mice, they found that mice without the molecule developed more liver metastases. They also followed up these studies in mice by comparing samples of normal and cancerous liver tissues of colorectal cancer patients. They discovered that the levels of IQGAP1 were reduced in the tumor microenvironment of liver metastases than in the normal tissue, suggesting that the tumor somehow communicates with its surroundings to tamp down the activity of this critical molecule.

This communication went both ways. Through a number of basic functional experiments, Dr. Kang and her colleagues showed that IQGAP1 interacts with and suppresses a powerful signaling molecule called TGF-beta receptor that tells normal cells that surround a tumor cell to become tumor-promoting cells.

"We think that tumor cells come into the liver and give orders to the signaling molecules in the surrounding normal cells to reduce the amount of IQGAP1, thereby creating a good tumor microenvironment for themselves," Dr. Kang says. "If we can understand exactly how they do this, then we may be able to uncover new therapeutic targets for liver metastasis."


'/>"/>
Contact: Joe Dangor
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. MicroRNA molecule may serve as biomarker, target for brain metastases in breast cancer patients
2. Beta-catenin molecule is required for tooth root formation
3. Mayo Clinic researchers find new molecule to target in pancreatic cancer treatment
4. CWRU School of Medicine researchers discover new molecule linked to late-stage breast cancer
5. New small molecule inhibitor could be a safe and first-line treatment for metastatic breast cancer
6. Looking for the anti-Alzheimers molecule -- A new approach to treating a devastating disease
7. Fat molecule ceramide may factor in muscle loss in older adults
8. New developments reveal a molecule with a promising function in terms of cancer treatment.
9. Measuring molecules with the naked eye
10. Molecule shows effectiveness against drug-resistant myeloma
11. Molecule found that inhibits recovery from stroke
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... vcfo, a consulting firm that ... to announce the promotion of Mike Mackey to Regional Vice President of Southeast ... was responsible for managing client projects and overseeing vcfo financial consultants in the ...
(Date:6/23/2016)... ... ... Virginia Beach resident Sean Kelly suffered from depression after a long military career ... set out to accomplish a personal mission: a solo 50-mile paddle. Kelly decided to ... the story of another special operations veteran, Josh Collins, whom Kelly had served with ...
(Date:6/23/2016)... ... June 23, 2016 , ... Horizon Blue Cross Blue ... seeking relief from the crushing burden of sky-high health care costs, Superior Court ... their ruling ( http://www.judiciary.state.nj.us/opinions/a2913-15a2929-15.pdf ) the court provided some analysis of the ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... has been approved to train physicians within its Graduate Medical Education program, this ... (ACGME) means MHS can begin enrolling doctors for residency training that will begin ...
(Date:6/23/2016)... , ... June 23, 2016 , ... King Kullen’s Shop ... offering service to yet another location: Garden City Park. This is the fourth store ... , Online grocery delivery service is offered by King Kullen and allows customers to ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016  Consumers have taken a more active ... more emphasis on patient outcomes. ... the pharmaceutical industry have evolved beyond just providing ... are focusing on becoming more patient-oriented across their ... services that improve health. ...
(Date:6/24/2016)... 24, 2016  Collagen Matrix, Inc., ("Collagen Matrix") ... manufacturing of collagen and mineral based medical devices ... Bill Messer has joined the company ... leverage the growing portfolio of oral surgery, neurosurgery, ... Bill joins the Collagen Matrix executive team as ...
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
Breaking Medicine Technology: